Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
For over 20 years Streamline Health has provided solutions that address the fundam...
For over 20 years Streamline Health has provide...
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing d...
Intec Pharma is a clinical-stage biopharmaceuti...
Natus is a leading provider of healthcare products and services used for the scree...
Natus is a leading provider of healthcare produ...
Sorrentoâs lead programs with short-term milestones consist of two clinical stag...
Sorrentoâs lead programs with short-term mile...
Knowledge Begets Confidence. Founded by proven and trusted Pharmaceutical and Medi...
Knowledge Begets Confidence. Founded by proven ...
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical com...
Founded in Lyon, France in 2004, ERYTECH is a c...
We are a clinical stage biopharmaceutical company focused on harnessing powerful b...
We are a clinical stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.